Whether working with sophisticated in-house counsel at a large pharmaceutical company or an individual inventor with little experience in the patent process, Russell Timm’s practice is based on the premise that a patent is not an end in and of itself, but rather a tool to achieve business objectives. When it comes to the patenting process, Dr. Timm has a particular interest in the areas of patent-eligible subject matter, double patenting and terminal disclaimers, patent term adjustment, and the differences in the patenting process in countries around the world.
Working with both US and foreign colleagues, Dr. Timm has pursued patent protection for his clients’ inventions in more than forty national and multinational patent offices, from Europe and Japan to Costa Rica and the UAE. His clients’ technologies encompass therapeutic antibodies and ADCs, agricultural biotechnology, disease and infection diagnostics, vaccines, human and animal health products, novel pharmaceuticals, screening methods, RNA interference and complex materials.
Dr. Timm’s graduate research involved analyzing the effect of androgens on the expression of a high-affinity carnitine transporter.
District of Columbia
United States Patent and Trademark Office